ArticleOncoimmunology2021
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Pierre Dillard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it
ArticleOncoimmunology2021
Pierre Dillard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.